FDA To Retain Staff, Despite User Fee Reauthorization Delays
This article was originally published in The Gray Sheet
Executive Summary
No layoff notices will be sent to FDA staff, despite delays in reauthorizing user fee legislation, set to expire Sept. 30
You may also be interested in...
Chart: Hill Roundup: What Congress Did And Didn't Do Before Leaving Town
Hill Roundup: What Congress Did And Didn't Do Before Leaving Town
FDA User Fee Reauthorization Passes House, Awaits Conference
The House passed broad-based FDA legislation July 11 that includes a package to reauthorize the medical device user fee program
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.